Sarah K Tasian, MD

Associate Professor of Pediatrics (Oncology) at the Children's Hospital of Philadelphia
Member, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania
Chief, Hematologic Malignancies Program, Children's Hospital of Philadelphia
Joshua Kahan Endowed Chair in Pediatric Leukemia Research, Children's Hospital of Philadelphia
Department: Pediatrics
Contact information
Children's Hospital of Philadelphia
Department of Pediatrics, Division of Oncology and Center for Childhood Cancer Research
University of Pennsylvania School of Medicine and Abramson Cancer Center
3501 Civic Center Boulevard, CTRB 3056
Philadelphia, PA 19104
Department of Pediatrics, Division of Oncology and Center for Childhood Cancer Research
University of Pennsylvania School of Medicine and Abramson Cancer Center
3501 Civic Center Boulevard, CTRB 3056
Philadelphia, PA 19104
Email:
tasians@chop.edu
tasians@chop.edu
Publications
Links
Search PubMed for articles
Tasian CHOP Faculty Profile
CHOP Hematologic Malignancies research program
Tasian Laboratory
Search PubMed for articles
Tasian CHOP Faculty Profile
CHOP Hematologic Malignancies research program
Tasian Laboratory
Education:
BS, BA (Biological Sciences, Psychology)
University of Notre Dame, 1999.
MD (Medicine)
Baylor College of Medicine, 2004.
PhD (Clinical and Translational Oncology programme)
Universiteit Utrecht, 2027.
Permanent linkBS, BA (Biological Sciences, Psychology)
University of Notre Dame, 1999.
MD (Medicine)
Baylor College of Medicine, 2004.
PhD (Clinical and Translational Oncology programme)
Universiteit Utrecht, 2027.
Description of Clinical Expertise
I have clinical expertise in the care of children, adolescents, and young adults with hematologic malignancies, particularly those with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and juvenile myelomonocytic leukemia (JMML). My particular clinical interests include integration of comprehensive leukemia genetic data with therapy selection for children with high risk newly-diagnosed and relapsed ALL and AML, CML, and JMML with a focus on precision medicine treatment approaches.I serve as Chief of the Hematologic Malignancies Program at the Children's Hospital of Philadelphia and attend on the inpatient leukemia/lymphoma service and outpatient clinic. I have procedural expertise in bone marrow aspiration and biopsy, lumbar punctures (spinal taps), Ommaya reservoir taps, administration of intrathecal chemotherapy, and skin biopsies for germline testing.
Description of Other Expertise
I am a primary clinical mentor in Hematologic Malignancies for first, second, third, and fourth year pediatric hematology-oncology fellows and closely supervise their patient care in the inpatient and outpatient clinical settings. I also teach and supervise pediatric residents in the inpatient setting.Description of Research Expertise
My overarching career goal as an academic pediatric oncologist and translational physician-scientist is to develop successful precision medicine therapies for children with high-risk leukemias aimed at decreasing relapse risk, minimizing toxicity, and improving long-term survival. My independent research program focuses upon identification of targeted therapeutic strategies for childhood leukemias via (1) mechanistic interrogation of aberrant signal transduction networks and preclinical testing of kinase and other small molecule inhibitors in genetic subtypes of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), (2) preclinical testing of chimeric antigen receptor (CAR) T cell immunotherapies for high-risk AML and ALL, and (3) early-phase clinical investigation of targeted inhibitors and cell therapies for children with leukemia and associated correlative biology studies through the Children’s Oncology Group (COG), Leukemia & Lymphoma Society Pediatric Acute Leukemia (LLS PedAL) consortium, and other national and international leukemia/cell therapy consortia. I am also an experienced early-phase clinical trialist and a member of the COG ALL executive committee and relapse subcommittee, the COG Myeloid Diseases executive committee (Vice-Chair of Relapse), and the LLS PedAL executive committee (Clinical Trials Leader).My laboratory has particular expertise in preclinical evaluation of small molecule inhibitors and CAR T cells in ALL and AML patient-derived xenograft models, as well as in phosphosignaling analyses and measurement of patients’ molecular responses to targeted inhibitors. Successful integration of my laboratory’s bench-based and clinical correlative studies has led to multiple trials testing targeted therapies in children with high-risk leukemias, many of which I also lead or co-lead.
Current Tasian laboratory members:
Camilo Arenas Merizalde, BS (research technician II)
Tommaso Balestra, PhD (post-doctoral fellow)
Diego Bárcenas López, PhD (post-doctoral fellow)
Shubhmita Bhatnagar, PhD (scientist II/lab manager)
Jackson Dardis, BS (research technician II)
Sarah Haines, BS (research technician III)
Anna Mai, MS (research technician III)
Ritul Sharma, PhD (post-doctoral fellow)
CHOP Hematologic Malignancies Program administrative & clinical research team:
Tasleema Patel, BA (program manager)
Maria Mezher, MD (clinical research coordinator)
Selected Publications
Tasian SK, Sabnis H, Cooper TM, Bautista Sirvent FJ, Petit A, Kutny M, Krieger E, Schuettpelz L, Kim A, Borgman A, Frankel S, Butturini A, Lu L, Murray K, Zwaan CM: A phase 1/2, open-label study evaluating the efficacy, safety, and pharmacokinetics of luveltamab tazevibulin in infants and children < 12 years of age with CBFA2T3::GLIS2 acute myeloid leukemia. JCO Page: TPS10074, June 2025 Notes: Poster presentation at ASCO 2025 annual meeting.Connor P, Ribeiro R, Catala A, Norton A, Schündeln M, Hasabou N, Delgado D, Heinloth A, Hill J, Gill S, Chen N, Tasian SK, Locatelli F: Biological Activity and Safety of Gilteritinib in Sequential Combination with Chemotherapy in Pediatric Patients with R/R FLT3-ITD AML: Interim Results From a Multi-Center Open-Label Phase 1/2 Trial. Hemasphere Page: PF528, June 2025 Notes: EHA 2025 annual meeting (poster presentation by a collaborator).
Gore L and Tasian SK: Exploring the Management of Pediatric Relapsed/Refractory Acute Leukemia. OncLive May 2025 Notes: https://www.onclive.com/news-network/exploring-the-management-of-pediatric-relasped-refractory-acute-leukemia
Ayyadevara VSSA, Wertheim G, Gaur S, Chukinas JA, Loftus JP, Lee SJ, Kumar A, Swaminathan S, Bhansali RS, Childers W, Geng H, Milne TA, Hua X, Bernt KM, Besson T, Shi J, Crispino JD, Carroll M, Tasian SK*, Hurtz C* (*co-senior authors): DYRK1A inhibition results in MYC and ERK activation rendering KMT2A-R acute lymphoblastic leukemia cells sensitive to BCL2 inhibition. Leukemia 39(5): 1078-1089, May 2025.
Egan G and Tasian SK: Precision medicine for high-risk gene fusions in pediatric AML: a focus on KMT2A, NUP98, and GLIS2 rearrangements. Blood 145: 2574-2586, May 2025.
Werner J, Lee AG, Zhang C, Abelson S, Xirenayi S, Rivera J, Yousuf K, Shin H, Patiño-Escobar B, Bachl S, Mandal K, Barpanda A, Ramos E, Izgutdina A, Chaudhuri S, Temple WC, Bhatnagar S, Dardis JK, Meyer J, Morales C, Meshinchi S, Loh ML, Braun B, Tasian SK, Wiita AP, Stieglitz E: Cellular immunotherapy targeting CLL-1 for juvenile myelomonocytic leukemia. Nat Commun 16: 3804, Apr 2025.
Tasian SK: Insights on Blinatumomab in Pediatric B-ALL. VuMedi April 2025 Notes: http://www.vumedi.com/video/blinatumomab-strategies-in-childrens-oncology-group-trials-and-new-standards-of-care-in-b-all/
Pham-Danis C, Novak AJ, Danis E, McClellan SM, Leach L, Yarnell MC, Ebmeier CC, Tasian SK, Kohler ME: Restoration of LAT activity improves CAR T cell sensitivity and persistence in response to antigen-low acute lymphoblastic leukemia. Cancer Cell 43: 482-502, Mar 2025.
Grenier JM, Tasian SK, Stieglitz E, Abdullaev Z, Wertheim GB, Li MM, Phillips CA.: Azacytidine Monotherapy in an Infant With Mosaic NRAS-Driven Juvenile Myelomonocytic Leukemia. Pediatr Blood Cancer Mar 2025.
Balestra T, Niswander LM, Bagashev A, Loftus JP, Ross SL, Chen RK, McClellan SM, Junco JJ, Bárcenas López DA, Rabin KR, Fry TJ, Tasian SK: Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia. Leukemia 39(3): 555-567, Mar 2025.